Abstract:The serotonin 1A receptor has been linked to both the pathophysiology of major depressive disorder (MDD) and the antidepressant action of serotonin reuptake inhibitors. Most PET studies of the serotonin 1A receptor in MDD used the receptor antagonist radioligand, [carbonyl- C]WAY100635; however the interpretation of the combined results has been contentious owing to reports of higher or lower binding in MDD with different outcome measures. The reasons for these divergent results originate from several sources, including properties of the radiotracer itself, which complicate its quantification and interpretation; as well as from previously reported differences between MDD and healthy volunteers in both reference tissue binding and plasma free fraction, which are typically assumed not to differ. Recently, we have developed two novel hierarchical multivariate methods which we validated for the quantification and analysis of [ C]WAY100635, which show better accuracy and inferential efficiency compared to standard analysis approaches. Importantly, these new methods should theoretically be more resilient to many of the factors thought to have caused the discrepancies observed in previous studies. We sought to apply these methods in the largest [ C]WAY100635 sample to date, consisting of 160 individuals, including 103 MDD patients, of whom 50 were not-recently-medicated and 53 were antidepressant-exposed, as well as 57 healthy volunteers. While the outcome measure discrepancies were substantial using conventional univariate analysis, our multivariate analysis techniques instead yielded highly consistent results across PET outcome measures and across pharmacokinetic models, with all approaches showing higher serotonin 1A autoreceptor binding potential in the raphe nuclei of not-recently-medicated MDD patients relative to both healthy volunteers and antidepressant-exposed MDD patients. Moreover, with the additional precision of estimates afforded by this approach, we can show that while binding is also higher in projection areas in this group, these group differences are approximately half of those in the raphe nuclei, which are statistically distinguishable from one another. These results are consistent with the biological role of the serotonin 1A autoreceptor in the raphe nuclei in regulating serotonin neuron firing and release, and with preclinical and clinical evidence of deficient serotonin activity in MDD due to over expression of autoreceptors resulting from genetic and/or epigenetic effects. These results are also consistent with downregulation of autoreceptors as a mechanism of action of selective serotonin reuptake inhibitors. In summary, the results using multivariate analysis approaches therefore demonstrate both face and convergent validity, and may serve to provide a resolution and consensus interpretation for the disparate results of previous studies examining the serotonin 1A receptor in MDD.

Comparison of activation ability between feline and bovine oocytes.

Molecular Imaging of Striatal Dopamine Transporters in Major Depression—a Meta-Analysis

An Electronic Voltage and Frequency Controller for Single-Phase Self-Excited Induction Generators for Pico Hydro Applications

123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study

Transitional Probabilities Are Prioritized over Stimulus/Pattern Probabilities in Auditory Deviance Detection: Memory Basis for Predictive Sound Processing

Comparison of the Effectiveness of Duloxetine in Depressed Patients with and Without a Family History of Affective Disorders in First-Degree Relatives.

Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB

Sex Differences in Diencephalon Serotonin Transporter Availability in Major Depression

Variability in the serotonin transporter gene and increased risk for major depression with melancholia

Changes of dopamine transporters in major depression and Parkinson disease

PET Imaging of the Serotonin 1A Receptor in Major Depressive Disorder: Hierarchical Multivariate Analysis of [ C]WAY100635 Overcomes Outcome Measure Discrepancies

Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain

Further studies on platelet serotonin transporter binding in depression

Putamen Structure and Function in Familial Risk for Depression: A Multimodal Imaging Study

Serotonin transporter availability increases in patients recovering from a depressive episode

Association between reduced white matter integrity in the corpus callosum and serotonin transporter gene DNA methylation in medication-naive patients with major depressive disorder

Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression

Awakening to the occupational health problems.

Platelet associated IgG, platelet survival, and platelet sequestration in thrombocytopenic states

Association study on 5-HT 2A receptor gene T102C polymorphism and the concentration of gray matter in patients with major depressive disorder

Studies with (plus)--octanoylcarnitine in experimental diabetic ketoacidosis.